Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company, is making significant strides in the development of a weight-loss drug that could shake up the highly competitive obesity ...
Industry experts expect many more Americans will do the same as those drugs’ explosive popularity, fueled by their ability to help people lose weight, reverberates across the retail sector. One in ...
Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...
In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for 2024 by $3 billion at the time of its Q2 report. It now anticipates a ...